22 September, 2016
Shearman & Sterling advised Jacobson Pharma Corporation Limited (Jacobson Pharma) on its global offering and initial public offering on the Main Board of The Stock Exchange of Hong Kong Limited. BOCI Asia Limited acted as the sole sponsor, sole global coordinator, sole bookrunner, and sole lead manager.
Morrison & Foerster represented the sole sponsor, BOCI Asia Limited, a subsidiary of BOC International Holdings Limited providing investment banking services. Ven Tan, managing partner of Morrison & Foerster’s Hong Kong office and head of the Hong Kong capital markets team, led the deal team, which also included Samuel Ng, Benjamin Wang, Grace Yeung, and Euzane Lee.
“We are proud to have played a key role in Jacobson Pharma’s IPO, which will enable the company to expand beyond Hong Kong and become a leading brand throughout the Asia Pacific region,” Mr. Tan said. “This is just the latest example of MoFo’s strength in pharmaceutical sector–related capital markets transactions, which are a key component of our extensive practice offering that also includes a strong expertise in technology deals.”
The Shearman & Sterling team was led by partner Colin Law (Hong Kong-Capital Markets); with support from counsel Edward Bong (Hong Kong-Capital Markets); and associates Clement Jiang, Marshall Chu, Steven Wu (Hong Kong-Capital Markets) and Stella Hu (Beijing-Capital Markets).
Jacobson Pharma is the largest generic drug company in Hong Kong with more than 30 percent share of the total generic drug market since 2012.
